United Kingdom · Question · Written question
UIN 142089
Tixagevimab/cilgavimab
Introduced
17 March 2022
Last action
24 March 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
24 March 2022
Summary
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92097 and following the Conditional Marketing Authorisation awarded by the Medicines and Healthcare products Regulatory Agency on 17 March 202
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
17 March 2022
Written question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92097 and following the Conditional Marketing Authorisation awarded by the Medicines and Healthcare products Regulatory Agency on 17 March 202
Source: Commons
24 March 2022
Answer
We are unable to provide the information requested as it is commercially sensitive. Any public announcement on the procurement of treatments would be made after an agreement is reached with companies. The Department is scoping the potential introduction o...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-03-17/142089
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1452143
- uk · wq-1452143 · source updated 24 March 2022